ReviewJornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia2021
Malignant pleural mesothelioma: an update.
Review in Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma.Thoracic cancer · 2026Article
- Epidermal growth factor receptor-targeted near-infrared photoimmunotherapy for malignant pleural mesothelioma.Lung cancer (Amsterdam, Netherlands) · 2026Article
- Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Review
- Emerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview.Thoracic cancer · 2026Review
- Cytopathologic Features of Metastatic Malignant Mesothelioma With SMARCB1 (INI-1) Deficient Diagnosed by Ultrasound-Guided Fine-Needle Aspiration: A Case Report.Diagnostic cytopathology · 2026Article
- Hidden in plain sight: a narrative review on environmental exposures and the fight against mesothelioma.Journal of thoracic disease · 2026Review
- Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers.Current oncology (Toronto, Ont.) · 2026Review
- Localized peritoneal epithelioid clear cell subtype mesothelioma: a case report and literature review.Frontiers in oncology · 2026Article
- The Prognostic Significance of BRCA1-Associated Protein 1(BAP1) in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis.Clinical Medicine Insights. Oncology · 2026Article
- Cystic epithelioid malignant mesothelioma of the mesentery with rapid postoperative metastasis: an unusual case report.Frontiers in medicine · 2026Article
- A novel malignant mesothelioma organoids-T cell co-culture platform for personalized immunochemotherapy testing.Scientific reports · 2025Article
- Positron emission tomography/computed tomography in risk-factor-negative young female with malignant pleural mesothelioma: A case report and review of literature.World journal of clinical cases · 2025Article
- Long-term survival of nonoccupational pleural mesothelioma: a case report and review of the literature.Journal of medical case reports · 2025Review
- A Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value.Journal of clinical medicine · 2025Article
- The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions.Cancers · 2025Review
- Computer-Aided Discovery of Natural Compounds Targeting the ADAR2 dsRBD2-RNA Interface and Computational Modeling of Full-Length ADAR2 Protein Structure.International journal of molecular sciences · 2025Article
- Prognostic Value of Chest CT Volumetric Analysis in Patients with Malignant Pleural Mesothelioma.Journal of clinical medicine · 2025Article
- Combining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives.Oncology research · 2025Review
- Mortality rate for mesothelioma as a basic cause in the period 2017-2022 in Chile.Ecancermedicalscience · 2025Article
- Concomitant diagnosis of hypersensitivity pneumonitis and localized epithelioid mesothelioma: a rare case report.Einstein (Sao Paulo, Brazil) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant mesotheliomas are rare types of cancers that affect the mesothelial surfaces, usually the pleura and peritoneum. They are associated with asbestos exposure, but due to a latency period of more than 30 years and difficult diagnosis, most cases are not detected until they reach advanced stages. Treatment options for this tumor type are very limited and survival ranges from 12 to 36 months. This review discusses the molecular physiopathology, current diagnosis, and latest therapeutic options for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.